A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Phase 3
750
about 6.8 years
18+
Male only
23 sites in AZ, CA, CO +13
What this study is about
Researchers are testing whether xaluritamig plus abiraterone is better than the standard treatment (docetaxel, cabazitaxel, or abiraterone) for men with metastatic castration-resistant prostate cancer who have not had chemotherapy before. The trial will last about 2 years and involve approximately 750 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Abiraterone acetate
- 2.Take Cabazitaxel
- 3.Take Docetaxel
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Antineoplastic Agent [TC] (Cytochrome P450 17A1 Inhibitors), cabazitaxel, docetaxel
oral, injection, intravenous, infusion
Primary: OS
Secondary: Accumulation Ratio of the AUC Over the Dosing Interval for Xaluritamig, Area Under the Concentration-time Curve (AUC) Over the Dosing Interval of Xaluritamig, Change From Baseline Over Time at Each Assessment in BPI-SF Pain Interference Scale, Change From Baseline Over Time at Each Assessment in BPI-SF Worst Pain Score, Change From Baseline Over Time at Each Assessment in Brief Pain Inventory - Short Form (BPI-SF) Pain Intensity Scale, Change From Baseline Over Time at Each Assessment in European Quality of Life (EuroQol) 5 Domain 5 Level Scale (EQ-5D-5L) Utility Score, Change From Baseline Over Time at Each Assessment in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score and Subscale Scores, Change From Baseline Over Time at Each Assessment in the EQ-5D-5L Visual Analogue Scale (VAS)
Oncology